MEDTE:PA:PA-BNP Paribas Easy ECPI Global ESG Med Tech UCITS ETF EUR Capitalisation (EUR)

ETF | Others |

Last Closing

USD 8.7692

Change

-0.07 (-0.80)%

Market Cap

N/A

Volume

5.59K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

-0.05 (-0.11%)

USD 61.53B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

-2.00 (-0.37%)

USD 12.47B
WRD:PA HSBC ETFs Public Limited Compa..

-0.17 (-0.49%)

USD 10.38B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

-2.92 (-1.21%)

USD 8.83B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

-1.70 (-0.37%)

USD 8.12B
WLD:PA Lyxor UCITS MSCI World D-EUR

-1.69 (-0.49%)

USD 7.14B
HHH:PA HSBC ETFs Public Limited Compa..

-0.20 (-0.37%)

USD 7.04B
LCWD:PA Multi Units Luxembourg - Lyxor..

-0.09 (-0.50%)

USD 6.51B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

-1.17 (-0.30%)

USD 5.52B
S500:PA Amundi S&P 500 ESG UCITS ETF A..

-0.78 (-0.50%)

USD 5.01B

ETFs Containing MEDTE:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.17% 33% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.17% 33% F 53% F
Trailing 12 Months  
Capital Gain 15.55% 37% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.55% 37% F 57% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.60% 25% F 37% F
Dividend Return 1.60% 23% F 35% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 3.48% 92% A 96% N/A
Risk Adjusted Return 45.92% 35% F 60% D-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.